Cargando…
PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application
Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predicti...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore srl
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614301/ https://www.ncbi.nlm.nih.gov/pubmed/36305021 http://dx.doi.org/10.32074/1591-951X-803 |